Mild VI* | MSVI* | Blindness | Any VI* | |||||
n/N | % (95% CI) | n/N | % (95% CI) | n/N | % (95% CI) | n/N | % (95% CI) | |
Men (years) | ||||||||
50–59 | 4/340 | 1.2 (0 to 2.3) | 1/346 | 0.3 (0 to 0.9) | 0/350 | 0 (0 to 0) | 10/340 | 2.9 (1.1 to 4.7) |
60–69 | 25/595 | 4.2 (2.6 to 5.8) | 15/613 | 2.5 (1.2 to 3.7) | 1/622 | 0.2 (0 to 0.5) | 55/595 | 9.2 (6.9 to 11.6) |
70–79 | 28/277 | 10.1 (6.5 to 13.7) | 20/319 | 6.3 (3.6 to 8.9) | 1/336 | 0.3 (0 to 0.9) | 64/277 | 23.1 (18.1 to 28.1) |
80+ | 8/56 | 14.3 (4.8 to 23.7) | 14/80 | 17.5 (9.0 to 26.0) | 1/88 | 1.1 (0 to 3.4) | 15/56 | 26.8 (14.8 to 38.8) |
Total | 65/1268 | 5.1 (3.9 to 6.3) | 50/1358 | 3.7 (2.7 to 4.7) | 3/1396 | 0.2 (0 to 0.5) | 144/1268 | 11.4 (9.6 to 13.1) |
Women (years) | ||||||||
50–59 | 13/566 | 2.3 (1.1 to 3.5) | 8/570 | 1.4 (0.4 to 2.4) | 3/576 | 0.5 (0 to 1.1) | 27/566 | 4.8 (3.0 to 6.5) |
60–69 | 40/530 | 7.6 (5.3 to 9.8) | 26/560 | 4.6 (2.9 to 6.4) | 0/570 | 0 (0 to 0) | 81/530 | 15.3 (12.2 to 18.4) |
70–79 | 36/239 | 15.1 (10.5 to 19.6) | 32/310 | 10.3 (6.9 to 13.7) | 0/341 | 0 (0 to 0) | 62/239 | 25.9 (20.3 to 31.5) |
80+ | 15/61 | 24.6 (13.5 to 35.7) | 17/96 | 17.7 (9.9 to 25.5) | 4/114 | 3.5 (0.1 to 6.9) | 29/61 | 47.5 (34.6 to 60.4) |
Total | 104/1396 | 7.5 (6.1 to 8.8) | 83/1536 | 5.4 (4.3 to 6.5) | 7/1601 | 0.4 (0.1 to 0.8) | 199/1396 | 14.3 (12.4 to 16.1) |
Full population (years) | ||||||||
50–59 | 17/906 | 1.9 (1.0 to 2.8) | 9/916 | 1.0 (0.3 to 1.6) | 3/926 | 0.3 (0 to 0.7) | 37/906 | 4.1 (2.8 to 5.4) |
60–69 | 65/1125 | 5.8 (4.4 to 7.1) | 41/1173 | 3.5 (2.4 to 4.5) | 1/1192 | 0.1 (0 to 0.2) | 136/1125 | 12.1 (10.2 to 14.0) |
70–79 | 64/516 | 12.4 (9.5 to 15.3) | 52/629 | 8.3 (6.1 to 10.4) | 1/677 | 0.2 (0 to 0.4) | 126/516 | 24.4 (20.7 to 28.1) |
80+ | 23/117 | 19.7 (12.3 to 27.0) | 31/176 | 17.6 (11.9 to 23.3) | 5/202 | 2.5 (0.3 to 4.6) | 44/117 | 37.6 (28.7 to 46.5) |
Total | 169/2664 | 6.3 (5.4 to 7.3) | 133/2894 | 4.6 (3.8 to 5.4) | 10/2997 | 0.3 (0.1 to 0.5) | 343/2664 | 12.9 (11.6 to 14.1) |
Standardised | 5.9 (5.0 to 6.8) | 4.0 (3.3 to 4.7) | 0.4 (0.1 to 0.6) | 12.0 (10.6 to 13.3) |
*Incidence was significantly higher in women than in men (p<0.05, Pearson χ2 test).
MSVI, moderate and serve visual impairment; VI, visual impairment.